SCHEMBL2306907

SCHEMBL2306907

CN(C)N1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27435759 0.96
Hydrochloric Acid SCHEMBL29673103 0.96
SCHEMBL378435 0.92
SCHEMBL4189631 0.92
SCHEMBL678889 0.89
SCHEMBL4178502 0.89 MGLL (0.30)
SCHEMBL4162255 0.89 MGLL (0.30)
Hydrochloric Acid SCHEMBL7350676 0.86 ALDH1A1 (0.30)
Hydrochloric Acid SCHEMBL16212815 0.86 ALDH1A1 (0.30)
SCHEMBL1577820 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3853220-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS Suzhou Zanrong Pharma Limited (CN) 2021-07-28 EP claimed
WO-2020057511-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS SUZHOU ZANRONG PHARMA LIMITED (CN) 2020-03-26 WO claimed
WO-2015188777-A1 CERTAIN PROTEIN KINASE INHIBITORS SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2015-12-17 WO claimed
EP-2190291-A1 HSP90 INHIBITORS WITH MODIFIED TOXICITY The Regents of the University of Colorado (US) 2010-06-02 EP claimed
WO-2009026548-A1 HSP90 INHIBITORS WITH MODIFIED TOXICITY THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2009-02-26 WO claimed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 EP disclosed
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2024-05-02 US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
US-20230365541-A1 INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-11-16 US disclosed
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 US disclosed
WO-2023072188-A1 KRAS G12D INHIBITORS AND USE THEREOF IN MEDICINE 贝达药业股份有限公司 2023-05-04 WO disclosed
EP-1916290-A1 A lubricating oil additive composition and method of making the same Chevron Oronite Company LLC (US) 2008-04-30 EP disclosed
US-20070078131-A1 Thieno-pyridinone derivatives as kinase inhibitors CELLTECH R&D LIMITED (GB) 2007-04-05 US disclosed
EP-1680429-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS Celltech R &amp; D Limited (GB) 2006-07-19 EP disclosed
WO-2005042540-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2005-05-12 WO disclosed
EP-0606382-B1 1,8-BENZONAPHTHYRIDINE DERIVATIVES AND ANTIMICROBIAL COMPOSITIONS BELLON LABOR SA ROGER (FR) 1998-05-13 EP disclosed
EP-0606382-A1 1,8-BENZONAPHTHYRIDINE DERIVATIVES AND ANTIMICROBIAL COMPOSITIONS LABORATOIRE ROGER BELLON (FR) 1994-07-20 EP disclosed
WO-1993007144-A1 1,8-BENZONAPHTHYRIDINE DERIVATIVES AND ANTIMICROBIAL COMPOSITIONS LABORATOIRE ROGER BELLON (FR) 1993-04-15 WO disclosed
EP-0536035-A1 1,8-Benzonaphthyridine derivatives and antimicrobial compositions LABORATOIRE ROGER BELLON (FR) 1993-04-07 EP disclosed